<Anchor>
I told you yesterday (10th) that the Corona 19 vaccine being developed by Pfizer, a US pharmaceutical company, showed more than 90% effectiveness in a phase 3 clinical trial. There is no, but it is said that there are many parts to prepare because it is a vaccine that requires cryogenic storage.
Reporter Nam Joo-hyun on the report.
<Reporter>
How was the 90% effectiveness of Pfizer's COVID-19 vaccine calculated?
Pfizer did not disclose the number of confirmed cases and age group, as well as the number of people who received the two vaccines, real and fake.
Under some assumptions, 86 people from the group who received the fake vaccine and 8 people from the group who received the real vaccine were infected.
The effect can be verified after commercialization, but the efficacy of 90% in clinical trials translates to a high possibility of suppressing Corona 19.
However, criticism has also been raised for not publishing the results in the form of a paper that has been evaluated by an expert group after completing the clinical trial completely.
It is not yet known whether this vaccine prevents mild COVID-19 symptoms in younger people, or if it has the effect of lowering the mortality rate in high-risk groups.
In addition, it is necessary to verify how long the COVID-19 prevention effect is maintained if the vaccine is given twice.
In particular, this vaccine is a new type of vaccine that has not existed before, so it requires a different preparation for transportation and management.
[Man-ki Song/Deputy Director of International Vaccine Research Institute: -20 degrees Celsius to -70 degrees Celsius (long-term) frozen storage is required.
We have to have a new refrigeration system.
So, it will take some time.]
The function and duration of the effect of this vaccine, which have not been revealed this time, are expected to be disclosed during the FDA emergency approval application process in the third week of this month.